HANSOH PHARMA(HK:03692) 智通财经网·2025-08-19 02:01Core Viewpoint - Hansoh Pharmaceutical (03692) reported a strong interim performance, leading to a nearly 6% increase in stock price, reflecting positive market sentiment towards the company's growth prospects [1] Financial Performance - The company achieved revenue of 7.434 billion RMB, representing a year-on-year increase of 14.27% [1] - Net profit attributable to shareholders was 3.135 billion RMB, up 15.02% year-on-year [1] - Earnings per share stood at 0.53 RMB, with an interim dividend proposed at 0.2316 HKD per share [1] Product Sales - Seven innovative drugs generated sales revenue in China, contributing approximately 61.45 billion RMB in sales from innovative and cooperative products, accounting for about 82.7% of total revenue [1] Strategic Developments - In June, the company announced the grant of exclusive overseas rights for the GLP-1/GIP dual receptor agonist HS-20094 to Regeneron, with a potential total amount exceeding 2 billion USD [1] - Clinical studies for HS-20094 have involved over 1,000 participants, and the drug is currently in Phase III clinical trials for obesity or overweight [1] - The company received an upfront payment of 80 million USD in July related to this agreement [1]